ArticleCell reports2020
The Cap-Snatching SFTSV Endonuclease Domain Is an Antiviral Target.
Article in Cell reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 50 citations in OpenAlex.
- Temporal Rewiring of Innate Immunity by Vector-Borne Viruses for Host-Directed Antiviral Therapy.International journal of molecular sciences · 2026Review
- Environmental, climatic, and social risk factors of severe fever with thrombocytopenia syndrome and the implications of climate change.One health (Amsterdam, Netherlands) · 2026Article
- Unraveling the complexities: A comprehensive review of severe fever with thrombocytopenia syndrome and its associated complications.iScience · 2026Review
- Transcriptomic and RNA Modification Landscape of Severe Fever with Thrombocytopenia Syndrome Virus Revealed by Nanopore Direct RNA Sequencing.Microorganisms · 2026Article
- Structure and function of the nairovirus cap-snatching endonuclease.Nucleic acids research · 2026Article
- Research progress on antiviral drugs and vaccines for severe fever with thrombocytopenia syndrome.Frontiers in immunology · 2026Review
- Pharmacophores of Influenza Virus PA Endonuclease Inhibitors.Advances in experimental medicine and biology · 2026Review
- Salvianolic acid A from Salvia miltiorrhiza identified as a cap-dependent endonuclease inhibitor for pathogenic arenaviruses.Acta pharmacologica Sinica · 2026Article
- Identification and Characterization of a Metal Binding-Independent Rift Valley Fever Virus Endonuclease Inhibitor.ACS infectious diseases · 2025Article
- Identification of Licoflavone C as a cap-dependent endonuclease inhibitor against severe fever with thrombocytopenia syndrome virus.Acta pharmacologica Sinica · 2025Article
- Genome-wide CRISPR screening identifies LRP1 as an entry factor for SFTSV.Nature communications · 2025Article
- Advancements in vaccine development and therapeutic approaches for severe fever with Thrombocytopenia Syndrome.Frontiers in cellular and infection microbiology · 2025Review
- Targeting stress induction of GRP78 by cardiac glycoside oleandrin dually suppresses cancer and COVID-19.Cell & bioscience · 2024Article
- Structural snapshots of phenuivirus cap-snatching and transcription.Nucleic acids research · 2024Article
- Modeling Heartland virus disease in mice and therapeutic intervention with 4'-fluorouridine.Journal of virology · 2024Article
- Emerging Tick-BorneMicroorganisms · 2023Review
- Article
- Biochemical and HDX Mass Spectral Characterization of the SARS-CoV-2 Nsp1 Protein.Biochemistry · 2023Article
- GRP78 Inhibitor YUM70 Suppresses SARS-CoV-2 Viral Entry, Spike Protein Production and Ameliorates Lung Damage.Viruses · 2023Article
- Glucosylceramide is essential for Heartland and Dabie bandavirus glycoprotein-induced membrane fusion.PLoS pathogens · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Severe fever with thrombocytopenia syndrome virus (SFTSV) is a tick-borne virus with 12%-30% case mortality rates and is related to the Heartland virus (HRTV) identified in the United States. Together, SFTSV and HRTV are emerging segmented, negative-sense RNA viral (sNSV) pathogens with potential global health impact. Here, we characterize the amino-terminal cap-snatching endonuclease domain of SFTSV polymerase (L) and solve a 2.4-Å X-ray crystal structure. While the overall structure is similar to those of other cap-snatching sNSV endonucleases, differences near the C terminus of the SFTSV endonuclease suggest divergence in regulation. Influenza virus endonuclease inhibitors, including the US Food and Drug Administration (FDA) approved Baloxavir (BXA), inhibit the endonuclease activity in in vitro enzymatic assays and in cell-based studies. BXA displays potent activity with a half maximal inhibitory concentration (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.